Navigation Links
Institut Pasteur Korea -- DNDi come together for the fight against neglected diseases
Date:8/13/2013

August 13, 2013, S. Korea. A collaboration between the Drugs for Neglected Diseases Initiative (DNDi) and the Institut Pasteur Korea (IP-K) to spur the fight against neglected diseases has been established.

IP-K and DNDi have entered into a Master Research Agreement for collaboration in identification and development of safe, effective and affordable new treatments for patients suffering from neglected diseases. Under the terms of agreement, both parties will conduct various research programs including Leishmaniasis and Chagas disease for next two years.

According to the recent report from WHO, currently, leishmaniasis is responsible for estimated 20,000 to 30,000 deaths annually and about 7 to 8 million people worldwide are estimated to suffer from Chagas disease. However, the use of existing treatments are limited due to field-adaptability, drug resistance, toxicity or high price. Therefore, the necessity for development of new drugs that effectively treat the diseases and are adapted and affordable to the populations affected by the diseases is vital. This agreement constitutes a unique combination of DNDi's advanced knowledge and resources in the field of neglected diseases research with IP-K's innovative drug discovery technology and capabilities. Under this agreement, DNDi will provide access to targeted chemical diversity for IP-K to employ its visual-based high throughput screening technology, PhenomicScreenTM, in order to accelerate identification of promising drug candidates. Both organizations will also make available internal expertise and access to its own global networks to increase the chance to establish new joint research programs within the public domain.

Building on an initial partnership to work together in finding new therapeutics for neglected diseases in 2007, both organizations have successfully developed new assays and identified new hit compounds effective against leishmaniasis. The proven success of the joint research effort has prompted both parties to undertake a more committed and long standing partnership.

Dr. Michele Liuzzi, the CEO of IP-K, said, "This exciting new partnership with DNDi will provide the impetus to accelerate the development of urgently needed drugs to treat neglected diseases."

"Thanks to our past collaboration with IPK, important technological advancements were made in the field of neglected tropical disease research, notably through effective high throughput screening", said Dr Bernard Pcoul, Executive Director, DNDi. "IPK is an important actor in the field of R&D for these diseases."


'/>"/>

Contact: Jean Kim
publicrelations@ip-korea.org
82-318-018-8041
Institut Pasteur Korea
Source:Eurekalert

Related biology news :

1. Diabetes Research Institute develops oxygen-generating biomaterial
2. Space research institute honors Sen. Hutchison with Pioneer Award
3. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
4. Minneapolis Heart Institute selected to participate in Cardiovascular Cell Therapy Research Network
5. Cary Institute Hydrofracking Forum
6. Scripps Research Institute Professor Gerald F. Joyce elected to American Academy of Arts & Sciences
7. Scripps Research Institute scientists develop antidote for cocaine overdose
8. NJIT, Chinas Bengbu Glass Institute sign agreement for R&D, training
9. Merkin Family Foundation to fund next generation of Broad Institute scientists
10. Botanical institutions announce plans to create first online World Flora
11. TGen leads new National Institutes of Health study of brain tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks , ... industrial engineering, was today awarded as one of ... of the world,s most innovative companies. Ginkgo Bioworks ... for the real world in the nutrition, health ... work directly with customers including Fortune 500 companies ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica ... in people with peritoneal or pleural mesothelioma. Their findings are the subject of a ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of the ... brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing ... to its list of well-respected retailers. This list includes such fine stores as ...
Breaking Biology Technology: